Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001737287-24-000081
Filing Date
2024-12-10
Accepted
2024-12-10 16:53:55
Documents
3
Period of Report
2024-12-09

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1733867628.html 4  
1 FORM 4 wk-form4_1733867628.xml 4 3528
2 EX-24 dmessmer-allogenexsectio.htm EX-24 3795
3 dmessmer-allogenexsectio001.jpg GRAPHIC 221660
  Complete submission text file 0001737287-24-000081.txt   314150
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
MESSEMER DEBORAH M. (Reporting) CIK: 0001754424 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 241539181